SearchNewsletter
All guidelines

Aspirin for primary prevention of cardiovascular disease

3 recommendations USPSTF 2022 · ACC/AHA 2019 · ADA 2026 Updated Sept. 25, 2026

Recommendations

USPSTF2022Grade C/D

Adults 40 to 59 with 10-year CVD risk 10% or greater, no increased bleeding risk: individualize; small net benefit, shared decision (Grade C). Adults 60 or older: do not initiate aspirin for primary prevention (Grade D). Dose 81 mg/day. Net benefit shrinks with age as bleeding risk rises. Does not apply to secondary prevention. CRC benefit no longer included.

Verify at USPSTF (opens in a new tab)

ACC/AHA2019Grade Class 2b / 3: Harm

Low-dose aspirin (75-100 mg daily) might be considered for select adults 40 to 70 at higher ASCVD risk who are not at increased bleeding risk (Class 2b, LOE A). Do not give it routinely for primary prevention in adults over 70 (Class 3: Harm, B-R), or at any age when bleeding risk is increased (Class 3: Harm, C-LD). Still the current ACC/AHA primary prevention guideline.

Verify at ACC/AHA (opens in a new tab)

ADA2026Grade A

Diabetes: aspirin 75-162 mg/day may be considered for primary prevention when cardiovascular risk is increased, after a comprehensive discussion of the benefit versus the comparable increase in bleeding risk (A). Over age 70 the balance appears to favor harm, so it generally may not be recommended. For secondary prevention, use aspirin 75-162 mg/day in anyone with diabetes and a history of ASCVD (A); clopidogrel 75 mg/day if aspirin allergic (B).

Verify at ADA (opens in a new tab)

Who this applies to

  • Ages 40 to 59 with a 10-year cardiovascular risk of 10 percent or more and no increased bleeding risk: an individual decision with a small net benefit (USPSTF 2022, Grade C). People who value preventing a heart attack or stroke over avoiding a bleed are the ones more likely to gain.
  • Age 60 and older: do not start aspirin for primary prevention (Grade D).
  • ACC and AHA 2019: low-dose aspirin may be considered at 40 to 70 for higher risk without increased bleeding risk; not routinely over 70, and not for anyone at increased bleeding risk.
  • Secondary prevention after a heart attack, stroke, stent or peripheral artery disease is unchanged: aspirin continues.

How it is done in practice

  • Dose 81 mg daily. Bleeding risk rises with a history of ulcer or GI bleed, age, low platelets, coagulopathy, CKD, NSAIDs, steroids, anticoagulants, uncontrolled hypertension and heavy alcohol use.
  • Patients already taking aspirin for primary prevention: around age 75, raise stopping. Net benefit falls with age, and the ASPREE trial found no benefit and more major bleeding in healthy adults over 70. This is a deprescribing conversation, not an alarm.
  • Diabetes alone no longer justifies aspirin: the ASCEND trial found fewer vascular events but an offsetting rise in major bleeding. Apply the same risk-based approach.
  • Colorectal cancer prevention was removed from the recommendation in 2022 after longer follow-up failed to confirm the earlier signal.

What changed recently

The 2022 statement reversed the 2016 one, which had favored aspirin at 50 to 59 for cardiovascular and colorectal cancer prevention. Three 2018 trials (ASPREE, ARRIVE and ASCEND) showed a small benefit at most and a clear increase in major bleeding.

Points that matter in clinic

  • Aspirin is not a substitute for a statin and blood pressure control; those deliver more benefit with less harm.
  • A markedly elevated coronary artery calcium score is one of the factors the ACC and AHA (2019) list for weighing aspirin at 40 to 70, alongside a strong family history of premature heart attack.
  • If aspirin is continued in someone with a prior ulcer, a proton pump inhibitor cuts the GI bleeding risk.

More quick references